-
Alternative_name
N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide; Hetlioz; BMS 214778; VEC-162; MA 1; (1R-trans)-N-[[2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
-
Description
Tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA). It is used to treat non-24-hour sleep-wake disorder. The Ki values for binding affinity at melatonin receptors MT1 and MT2 receptor are 0.304 and 0.069 nM respectively in CHO–K1 cells. It shows greater affinity for the MT2 receptor which is believed to mediate circadian rhythm phase-shifting. It induces a potent, concentration-dependent inhibition of forskolin-stimulated cAMP accumulation in NIH-3T3 cells stably expressing human MT1 and MT2 receptors with EC₅₀ values of 0.74 nM and 0.1 nM repectively.
-
CAS Number
609799-22-6
-
Structure Available
True
-
Salt Form
False
-
Molecular Formula
C₁₅H₁₉NO₂
-
Molecular Weight
245.32
-
Cell Permeable
False
-
Purity
0.95
-
Solubilities
~2 mg/ml in DMSO
-
Handling
Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
-
Tag Line
A potent Dual Melatonin Receptor Agonist (DMRA)
-
Storage Condition
-20ºC
-
Shipping Condition
RT
-
Shelf Life
36months
-
MDL Number
MFCD09033789
-
PubChem CID
10220503
-
-
SMILES
CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2
-
InChi
InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
-
InChi Key
PTOIAAWZLUQTIO-GXFFZTMASA-N
-
-
MSDS Available
1